Company news

Anteris Technologies Global Corp. news in 2025

Anteris Technologies Global Corp.'s news releases, calls and decks from 2025, newest first.

View company

Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves

November 17, 2025

Anteris Announces Results for the Third Quarter of 2025

November 12, 2025

FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

November 3, 2025

Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year

October 28, 2025

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

October 27, 2025

Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

October 27, 2025

Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

October 15, 2025

Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders

September 19, 2025

Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

September 11, 2025

Anteris Announces Results for the Second Quarter of 2025

August 11, 2025

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

June 9, 2025

Anteris Announces Results for the First Quarter of 2025

May 13, 2025

Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV

March 31, 2025

Anteris Reports One-Year Patient Outcomes for DurAVR® THV

March 21, 2025

Anteris Reports 2024 Financial Results and Provides Corporate Update

March 12, 2025

Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays

February 28, 2025

Decks in 2025